GSK opens API facility in Scotland

By Flora Southey

- Last updated on GMT

iStock/ronniechua
iStock/ronniechua

Related tags Vaccine Immune system Aids

GlaxoSmithKline has officially opened its aluminium salts facility in Montrose, Scotland.

According to GSK, the facility represents a £44m investment which, when fully operational in 2019, will provide ingredients for more than 40 million vaccinations a year.

The company told in-PharmaTechnologist the plant will create 15 jobs, on a site which employs more than 450.

The salts plant is situated within GSK’s Montrose facility, which has been making drug ingredients – including APIs for respiratory and HIV vaccine products – for six decades.

UK shake-up

Last month, GSK announced​ it would restructure its UK network by suspending plans for its Ulverston, Italy-based biopharma plant.

In addition, the firm suggested it would sell its cephalosporin antibiotics business and associated facilities, and invest in HIV and respiratory drug capacity.

The company said it is simplifying its business by improving competitiveness of its manufacturing network and increasing focus on its core business.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Webinars

Headlines